Growth Metrics

Merck (MRK) Non-Current Debt (2016 - 2026)

Merck has reported Non-Current Debt over the past 18 years, most recently at $46.7 billion for Q1 2026.

  • Quarterly Non-Current Debt rose 39.39% to $46.7 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $46.7 billion through Mar 2026, up 39.39% year-over-year, with the annual reading at $46.8 billion for FY2025, 35.66% up from the prior year.
  • Non-Current Debt was $46.7 billion for Q1 2026 at Merck, roughly flat from $46.8 billion in the prior quarter.
  • Over five years, Non-Current Debt peaked at $46.8 billion in Q4 2025 and troughed at $28.1 billion in Q1 2023.
  • The 5-year median for Non-Current Debt is $34.0 billion (2025), against an average of $34.3 billion.
  • Year-over-year, Non-Current Debt fell 8.21% in 2023 and then skyrocketed 39.39% in 2026.
  • A 5-year view of Non-Current Debt shows it stood at $28.7 billion in 2022, then increased by 17.18% to $33.7 billion in 2023, then grew by 2.31% to $34.5 billion in 2024, then skyrocketed by 35.66% to $46.8 billion in 2025, then dropped by 0.16% to $46.7 billion in 2026.
  • Per Business Quant, the three most recent readings for MRK's Non-Current Debt are $46.7 billion (Q1 2026), $46.8 billion (Q4 2025), and $40.0 billion (Q3 2025).